Skip to content

Investigating the Role of Biomarkers in Predicting Outcome for COVID 19

COVID 19

Emergent experimental and anecdotal evidence has indicated that critically ill COVID-19 patients demonstrate two patient sub-types (called phenotypes). In one group the disease progresses slowly and patients have a low potential of developing mild respiratory failure, but in the other group, an exaggerated immune response (hyper-inflammation/cytokine storm) may be linked to the onset of precipitous respiratory failure, termed acute respiratory distress syndrome. This syndrome is responsible for a large portion of COVID-19 associated mortality. Thus, determining links between hyper-inflammation and acute respiratory distress syndrome in COVID-19 patients is of immediate importance. Blood samples will undergo a number of analyses to help us to understand as much as possible about COVID-19. We will also study any differences in physiologic and cytokine levels before and after patients are treated with immunomodulatory therapies as part of clinical care in COVID-19 patients.

null

Participation Requirements

  • Sex:

    ALL

  • Eligible Ages:

    0 and up

Participation Criteria

Inclusion Criteria:

* Patients admitted to VGH or SMH with confirmed COVID-19
* Admitted to the High Acuity Unit or Intensive Care Unit at VGH or SMH
* An arterial line is in place as part of clinical care. If arterial line is on longer insitu the sample will be collected to coincide with usual care blood collection. This will negate the need for additional venipuncture

Exclusion Criteria:

* Those who do not meet inclusion criteria

Study Location

Vancouver General Hospital
Vancouver General Hospital
Vancouver, British Columbia
Canada

Contact Study Team

Primary Contact

Mypinder Sekhon

[email protected]
Study Sponsored By
University of British Columbia
Participants Required
More Information
Study ID: NCT04363008